Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α‑Gal epitopes

Xing,Xiaowei; Zou,Zhenyu; He,Changzheng; Hu,Zilong; Liang,Kai; Liang,Wentao; Wang,Yufeng; Du,Xiaohui

doi:10.3892/ol.2019.10376

Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α‑Gal epitopes

Authors:
- Xiaowei Xing
- Zhenyu Zou
- Changzheng He
- Zilong Hu
- Kai Liang
- Wentao Liang
- Yufeng Wang
- Xiaohui Du
View Affiliations

Affiliations: Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Department of Hernia and Abdominal Wall Surgery, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100853, P.R. China, Department of Patient Admission Management, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: May 20, 2019 https://doi.org/10.3892/ol.2019.10376
Pages: 864-871

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common types of gastrointestinal malignancy. Traditional therapeutic options for CRC exhibit a limited effect. Adoptive cellular therapy has emerged as a new treatment strategy for CRC. Dendritic cells (DCs) are potent antigen‑presenting cells. Specific cytotoxic T lymphocytes (CTLs) activated by DCs pulsed with tumor lysate have been reported to be a safe and promising treatment approach for CRC. However, the antitumor effect of specific CTLs remains limited. The low immunogenicity of tumor‑associated antigens (TAAs) is the main reason for this limited therapeutic effect. In the present study, α‑gal epitopes were synthesized on the CRC cell line SW620 to increase the immunogenicity of TAAs. DCs were pulsed with α‑gal‑expressing tumor lysate and CTLs were activated by these DCs. The cytotoxicity of CTLs was measured in vitro. The results demonstrated that DCs pulsed with α‑gal‑expressing tumor lysate can increase the frequency of CD3+CD8+ CTLs and natural killer T cells, increase the level of tumor necrosis factor‑α produced by CTLs and enhance the cytotoxicity of CTLs against tumor cells. Therefore, this novel approach may be an effective treatment strategy for patients with CRC.

View Figures

View References

1	Adam R and Vinet E: Regional treatment of metastasis: Surgery of colorectal liver metastases. Ann Oncol. 15 (Suppl 4):iv103–iv106. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ramos A and Hemann MT: Drugs, bugs, and cancer: Fusobacterium nucleatum promotes chemoresistance in colorectal cancer. Cell. 170:411–413. 2017. View Article : Google Scholar : PubMed/NCBI
3	Khan K, Wale A, Brown G and Chau I: Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol. 20:12391–12406. 2014. View Article : Google Scholar : PubMed/NCBI
4	Castro JE and Kipps TJ: Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 29:15–29. 2016. View Article : Google Scholar : PubMed/NCBI
5	Schubert ML, Hückelhoven A, Hoffmann JM, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P and Schmitt M: Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia andlymphoma in the context of stem cell transplantation. Hum Gene Ther. 27:758–771. 2016. View Article : Google Scholar : PubMed/NCBI
6	Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al: Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 125:739–751. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, Zhang J, Li J and Pang Y: Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int. 2014:6038712014. View Article : Google Scholar : PubMed/NCBI
8	Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF and Warren EH: Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 35:131–141. 2012. View Article : Google Scholar : PubMed/NCBI
9	Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R and Li JJ: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 9:e938862014. View Article : Google Scholar : PubMed/NCBI
10	Baratin M, Kayibanda M, Ziol M, Romieu R, Briand JP, Guiller JG and Viguier M: Amino acid modifications in the wild type sequence p53 232–240 overcome the poor immunogenicity of this self tumour epitope. J Pept Sci. 8:327–334. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kalinski P: Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs. 10:526–535. 2009.PubMed/NCBI
12	Iorgulescu JB, Braun D, Oliveira G, Keskin DB and Wu CJ: Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 10:872018. View Article : Google Scholar : PubMed/NCBI
13	Galili U: Autologous tumor vaccines processed to express alpha-gal epitopes: A practical approach to immunotherapy in cancer. Cancer Immunol Immunother. 53:935–945. 2004. View Article : Google Scholar : PubMed/NCBI
14	Galili U, Clark MR, Shohet SB, Buehler J and Macher BA: Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. Proc Natl Acad Sci USA. 84:1369–1373. 1987. View Article : Google Scholar : PubMed/NCBI
15	Galili U: Anti-Gal: An abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology. 140:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
16	Abdel-Motal UM, Wigglesworth K and Galili U: Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine. 27:3072–3082. 2009. View Article : Google Scholar : PubMed/NCBI
17	Huai G, Qi P, Yang H and Wang Y: Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review). Int J Mol Med. 37:11–20. 2016. View Article : Google Scholar : PubMed/NCBI
18	Galili U: Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. Subcell Biochem. 32:1–23. 1999.PubMed/NCBI
19	Yao X, Dong Z, Zhang Q, Wang Q and Lai D: Epithelial ovarian cancer stem-like cells expressing α-gal epitopes increase the immunogenicity of tumor associated antigens. BMC Cancer. 15:9562015. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y, Li L, Liang K, Liang W, Sun H and Li R: Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 36:4535–4543. 2015. View Article : Google Scholar : PubMed/NCBI
22	Carluccio S, Delbue S, Signorini L, Setola E, Bagliani A, Della Valle A, Galli A, Ferrante P and Bregni M: Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer. J Cell Physiol. 230:1457–1465. 2015. View Article : Google Scholar : PubMed/NCBI
23	Hunyadi J, András C, Szabó I, Szántó J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, et al: Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I–II study. Pathol Oncol Res. 20:357–365. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, et al: Adoptive chemoimmunotherapy using activated αβ T cells for stage IV colorectal cancer. Anticancer Res. 36:3741–3746. 2016.PubMed/NCBI
25	Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, et al: Clinical study on the medical value of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study). Anticancer Res. 37:3941–3946. 2017.PubMed/NCBI
26	Wang GZ, Tang XD, Lü MH, Gao JH, Liang GP, Li N, Li CZ, Wu YY, Chen L, Cao YL, et al: Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prev Res (Phila). 4:1285–1295. 2011. View Article : Google Scholar : PubMed/NCBI
27	Shimizu H, Ito H, Kimura F, Togawa A, Yoshidome H, Ohtsuka M, Kato A, Nukui Y and Miyazaki M: Decreased cell-mediated immune status in colorectal cancer patients with hepatic metastasis. Hepatogastroenterology. 52:1106–1109. 2005.PubMed/NCBI
28	Kwak Y, Koh J, Kim DW, Kang SB, Kim WH and Lee HS: Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 7:81778–81790. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ho NI, Huis In't Veld LGM, Raaijmakers TK and Adema GJ: Adjuvants enhancing cross-presentation by dendritic cells: The key to more effective vaccines? Front Immunol. 9:28742018. View Article : Google Scholar : PubMed/NCBI
30	Ugur M and Mueller SN: T cell and dendritic cell interactions in lymphoid organs: More than just being in the right place at the right time. Immunol Rev. 289:115–128. 2019. View Article : Google Scholar : PubMed/NCBI
31	Chu WM: Tumor necrosis factor. Cancer Lett. 328:222–225. 2013. View Article : Google Scholar : PubMed/NCBI
32	Foged C, Hansen J and Agger EM: License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci. 45:482–491. 2012. View Article : Google Scholar : PubMed/NCBI
33	Gagnon SJ, Wang Z, Turner R, Damirjian M and Biddison WE: MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL. J Immunol. 171:2233–2241. 2003. View Article : Google Scholar : PubMed/NCBI
34	Guzmán-Flores JM and Portales-Pérez DP: Mechanisms of suppression of regulatory T-cells (Treg). Gac Med Mex. 149:630–638. 2013.(In Spanish). PubMed/NCBI
35	Schmidt A, Oberle N and Krammer PH: Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 3:512012. View Article : Google Scholar : PubMed/NCBI
36	Tian Y, Yuan C, Ma D, Zhang Y, Liu Y, Zhang W, Hou F and Cui B: IL-21 and IL-12 inhibit differentiation of Treg and TH17 cells and enhance cytotoxicity of peripheral blood mononuclear cells in patients with cervical cancer. Int J Gynecol Cancer. 21:1672–1678. 2011. View Article : Google Scholar : PubMed/NCBI
37	Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S and Taniguchi M: NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol. 4:4092013. View Article : Google Scholar : PubMed/NCBI
38	Robertson FC, Berzofsky JA and Terabe M: NKT cell networks in the regulation of tumor immunity. Front Immunol. 5:5432014. View Article : Google Scholar : PubMed/NCBI
39	Taniguchi M, Harada M, Dashtsoodol N and Kojo S: Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy. Proc Jpn Acad Ser B Phys Biol Sci. 91:292–304. 2015. View Article : Google Scholar : PubMed/NCBI
40	Furukawa K, Tanemura M, Miyoshi E, Eguchi H, Nagano H, Matsunami K, Nagaoka S, Yamada D, Asaoka T, Noda T, et al: A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes. PLoS One. 12:e01849012017. View Article : Google Scholar : PubMed/NCBI
41	Xue D, Liang Y, Duan S, He J, Su J, Zhu J, Hu N, Liu J, Zhao Y and Lu X: Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing α-Gal epitopes. Oncol Rep. 36:2843–2851. 2016. View Article : Google Scholar : PubMed/NCBI